Cynata Therapeutics Limited (CYYNF) Research

Cynata Therapeutics Limited, an Australian biotechnology company headquartered in Cremorne, specializes in developing and bringing to market its unique Cymerus™ mesenchymal stem cell (MSC) technology for a wide array of human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully completed Phase I clinical trials addressing graft-versus-host disease (GvHD). Beyond this, its development pipeline features CYP-004, currently in Phase III clinical trials for osteoarthritis, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. The company is also actively investigating treatments for numerous other medical conditions, including asthma, myocardial infarction (heart attack), coronary artery disease, acute respiratory distress syndrome (ARDS), brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis (IPF), and opportunities in renal transplantation. Crucially, Cynata has forged a strategic partnership with Fujifilm, which provides essential clinical and commercial manufacturing and supply services for its Cymerus-based therapeutic MSC products. Originally incorporated in 2003 as Eco Quest Limited, the company rebranded as Cynata Therapeutics Limited in October 2013.

Open Cynata Therapeutics Limited (CYYNF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.